{
  "docId": "019dd923-5ca1-7489-b638-e62bea0762fa",
  "docSlug": "78005f3a3554aa50",
  "documentTitle": "Refueling Innovation Engine Vaccines",
  "authorId": "McKinsey",
  "authorName": "McKinsey",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.333,
  "pageNumber": 24,
  "pageCount": 40,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "problem_statement",
  "function": "diagnose",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide highlights a 27% increase in time to market between 2003-08 and 2009-14.",
  "elementsJson": [
    "headline_text",
    "bar_chart_vertical",
    "bullet_list",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b638-e62bea0762fa/24",
  "deckHref": "/decks/019dd923-5ca1-7489-b638-e62bea0762fa",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b638-e62bea0762fa.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b638-e62bea0762fa#slide-24",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Vaccine trials are getting longer. This driven both by more advanced technology, and increased Regulatory hurdles",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-d3bb-700a-9da6-c7bd7b85d363",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.58,
        "x": 0.03,
        "y": 0.165
      },
      "kind": "chart",
      "text": "Average time in phase for successful phases, years",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11068134-3a28-4385-87d8-bd720baafe25",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.66,
        "y": 0.185
      },
      "kind": "list",
      "text": "Vaccine trials are getting longer. This driven both by more advanced technology, and increased Regulatory hurdles. Recruiting participants is becoming more difficult, especially as trials grow larger.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "010381b1-c770-43dd-afa1-3b4fd0d35fff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Time to market: +27%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd951-d3bb-700a-9da6-c89b86e4ae10",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.03,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "SOURCE: Pharmaprojects 2013",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "849a6451-a719-45df-9e46-95548f8de60c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.03,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "1 Anti-infective vaccine products including prophylactic vaccines and recombinant vaccines as defined by Pharmaprojects. Note that recombinant vaccine group may contain some therapeutic vaccines.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aadc8fce-50d9-4248-968a-51a89a34378d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "Time to market for vaccines is increasing, implying increasing costs and creating potential economic uncertainty",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e4d7330e-bde4-46d7-b226-55b3ee026141",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [
    {
      "metricRaw": "Time to market",
      "numberRaw": "+27%",
      "numberKind": "percent",
      "actionTitle": "Time to market for vaccines is increasing, implying increasing costs and creating potential economic uncertainty",
      "calloutText": "Vaccine trials are getting longer. This driven both by more advanced technology, and increased Regulatory hurdles",
      "numberScale": null,
      "numberValue": 27,
      "metricFamily": "other",
      "numberCurrency": null
    }
  ],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 27,
      "from": 24,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "aed78475-3aec-4aeb-9912-10ba1bb79adb",
      "evidence": "The deck highlights the increasing costs and economic uncertainty of vaccine development.",
      "position": 0,
      "objective": "What are the costs of inaction in vaccine innovation?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}